Timosaponin AIII Suppresses Hepatocyte Growth Factor-Induced Invasive Activity through Sustained ERK Activation in Breast Cancer MDA-MB-231 Cells

ATF2: A transcription factor that elicits oncogenic or tumor suppressor activities

(2014) Anindita Bhoumik et al.   CELL CYCLE

Curcumin induces the apoptosis of human monocytic leukemia THP-1 cells via the activation of JNK/ERK Pathways

(2012) Chu-Wen Yang et al.   BMC Complementary and Alternative Medicine

Magnolol Suppresses MetastasisviaInhibition of Invasion, Migration, and Matrix Metalloproteinase-2/-9 Activities in PC-3 Human Prostate Carcinoma Cells

(2010) Eun-Sun HWANG et al.   BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

The use of herbal medicines by people with cancer: a qualitative study

(2009) Christine Gratus et al.   BMC Complementary and Alternative Medicine

ERK and cell death: cadmium toxicity, sustained ERK activation and cell death

(2009) Patrick Martin et al.   FEBS Journal

ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence

(2009) Sebastien Cagnol et al.   FEBS Journal

Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer

(2009) Aye Aye Thike et al.   MODERN PATHOLOGY

Timosaponin AIII Is Preferentially Cytotoxic to Tumor Cells through Inhibition of mTOR and Induction of ER Stress

(2009) Frank W. King et al.   PLoS One

Timosaponin A-III Induces Autophagy Preceding Mitochondria-Mediated Apoptosis in HeLa Cancer Cells

(2008) L.-K. Sy et al.   CANCER RESEARCH

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9

(2008) C.-W. Lin et al.   MOLECULAR CANCER THERAPEUTICS